DLX5 and myelodysplastic syndrome: Although no statistical significance was showed of DLX5 methylation in MDS patients and controls (P = .063; Figure 2C), the level of DLX5 methylation in AML patients was markedly higher than in controls and MDS patients (both P < .001; Figure 2C).